Recruiting Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) NCT06796803 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more Locations Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China Zhongshan Hospital — Shanghai, Shanghai Municipality, China View Trial Details
Not Yet Recruiting Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion NCT07738055 Conditions Potentially Resectable Hepatocellular Carcinoma Locations Not specified View Trial Details
Not Yet Recruiting A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma NCT06143579 Conditions Potentially Resectable Hepatocellular Carcinoma Locations Not specified View Trial Details
